REGRESSION-BASED ASSESSMENT OF INCREASED LENGTH OF STAY DUE TO DRPS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS
Author(s)
Suhaib Muflih, PharmD, PhD, Other1, Lara Albiss, MSc2, eman M. massad, Sr., PhD3, Barry Bleidt, PharmD, PhD, RPh, FAPhA4;
1Imam Abdulrahman Bin Faisal University, Associate Professor, Dammam, Saudi Arabia, 2Jordan University of Science and Technology, Irbid, Jordan, 3The University of Jordan, amman, Jordan, 4Florida A & M University, Florida, FL, USA
1Imam Abdulrahman Bin Faisal University, Associate Professor, Dammam, Saudi Arabia, 2Jordan University of Science and Technology, Irbid, Jordan, 3The University of Jordan, amman, Jordan, 4Florida A & M University, Florida, FL, USA
OBJECTIVES: The unpredictable pattern of symptoms, progression, and response during Rheumatoid arthritis (RA) management highlighted the need for pharmacovigilance assessment. The purpose of this study is to estimate the additional cost due to the extra length of stay (LOS) attributed to drug-related problems (DRPs) among patients with RA
METHODS: A cross-sectional study with chart review was conducted at the rheumatology outpatient clinics in Jordan to assess pharmacovigilance status and cost saving among RA patients. Patients 18 years of age or older, taking at least one RA medication, and willing to voluntarily take part in the study were eligible to participate. Cipolle's technique was used to categorize DRPs into seven broad categories. The additional LOS was calculated by the difference between observed and expected LOS, assuming no DRPs in the regression model. The total cost per hospital day, stemmed from a previous study, was multiplied by the additional LOS to estimate the burden of ADRs.
RESULTS: A total of 225 patients with a mean age of 52±11 were included in this study (86% females). DM and hypertension affected around 24% and 39% of the individuals, respectively. The results showed that csDMARD monotherapy was the most recommended regimen among RA patients, followed by double-csDMARD (19.1%). A total of 3445 DRPs were identified, an average of 15.31 DRPs per patient. Unnecessary drug therapy (99.6%) and ineffective drug therapy (94.6%) were the most prevalent DRPs. The findings of the linear regression indicated that lower income was associated with to higher LOS (p=0.004), and the number of comorbidities was strongly correlated with LOS (P<0.002). An estimated cost-saving of $16,000 was associated with the additional LOS.
CONCLUSIONS: The impact of ADRs on longer length of hospital stay and significant additional healthcare expenses stresses the importance of individualized patient-centered interventions. The cost saving justifies investment in ADRs monitoring programs
METHODS: A cross-sectional study with chart review was conducted at the rheumatology outpatient clinics in Jordan to assess pharmacovigilance status and cost saving among RA patients. Patients 18 years of age or older, taking at least one RA medication, and willing to voluntarily take part in the study were eligible to participate. Cipolle's technique was used to categorize DRPs into seven broad categories. The additional LOS was calculated by the difference between observed and expected LOS, assuming no DRPs in the regression model. The total cost per hospital day, stemmed from a previous study, was multiplied by the additional LOS to estimate the burden of ADRs.
RESULTS: A total of 225 patients with a mean age of 52±11 were included in this study (86% females). DM and hypertension affected around 24% and 39% of the individuals, respectively. The results showed that csDMARD monotherapy was the most recommended regimen among RA patients, followed by double-csDMARD (19.1%). A total of 3445 DRPs were identified, an average of 15.31 DRPs per patient. Unnecessary drug therapy (99.6%) and ineffective drug therapy (94.6%) were the most prevalent DRPs. The findings of the linear regression indicated that lower income was associated with to higher LOS (p=0.004), and the number of comorbidities was strongly correlated with LOS (P<0.002). An estimated cost-saving of $16,000 was associated with the additional LOS.
CONCLUSIONS: The impact of ADRs on longer length of hospital stay and significant additional healthcare expenses stresses the importance of individualized patient-centered interventions. The cost saving justifies investment in ADRs monitoring programs
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE452
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)